Posted by Michael Wonder on 29 Aug 2018
Cancer charities dismayed after ‘new generation’ therapy rejected as too expensive
29 August 2018 - A NICE committee said the cost of the drug was “too high for it to be considered a cost-effective use of NHS resources”.
Cancer charities have reacted with dismay after a “new generation” therapy that has proven to save lives has been rejected for widespread NHS use by health officials on cost grounds.
NICE has published draft guidance stating that axicabtagene ciloleucel, also known as Yescarta, is not recommended for NHS use for the 4,800 patients in the UK with aggressive sub-types of non-Hodgkin lymphoma.
